| Literature DB >> 23361056 |
E W de Bekker-Grob1, J M Rose, B Donkers, M-L Essink-Bot, C H Bangma, E W Steyerberg.
Abstract
BACKGROUND: Screening for prostate cancer (PC) may save lives, but overdiagnosis and overtreatment are serious drawbacks. We aimed to determine men's preferences for PC screening, and to elicit the trade-offs they make.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23361056 PMCID: PMC3593568 DOI: 10.1038/bjc.2013.5
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Considered attributes and attribute levels for prostate cancer screening
| Risk reduction of death from prostate cancer | 3.5% → 3.2% (10% relative risk reduction) |
| 3.5% → 2.8% (20% relative risk reduction) | |
| 3.5% → 2.5% (30% relative risk reduction) | |
| | 3.5% → 1.8% (50% relative risk reduction) |
| Screening interval | Every year |
| Every 2 years | |
| Every 3 years | |
| | Every 4 years (reference level) |
| Risk of unnecessary biopsy | 20% |
| 40% | |
| 60% | |
| | 80% |
| Risk of unnecessary treatment | 0% |
| 20% | |
| 50% | |
| | 80% |
| Out-of-pocket costs | €0 |
| €50 | |
| €100 | |
| €300 |
All attributes entered the analyses as numerical variates, except the attribute ‘screening interval'. This latter attribute was entered the analyses as a categorical variate with ‘every 4 years' as reference level.
Figure 1Overview of subjects accessing the study.
Characteristics of respondents, who filled in the discrete choice experiment
| | ||
|---|---|---|
| Characteristics | Mean | s.d. |
| Age (years) | 63.3 | 5.2 |
| Educational level | % | |
| Lower education | 95 | 22.5 |
| Intermediate education | 188 | 44.4 |
| Higher education | 140 | 33.1 |
| Household | | |
| Single, no living in children | 41 | 9.6 |
| Single, one or more living in children | 6 | 1.4 |
| With partner/family member, no living in children | 298 | 70.1 |
| With partner/family member, one or more living in children | 80 | 18.8 |
| Income (€/month) | | |
| 0–999 | 8 | 2.0 |
| 1000–1999 | 80 | 20.1 |
| 2000–2999 | 157 | 39.4 |
| 3000–3999 | 97 | 24.4 |
| >4000 | 56 | 14.1 |
| Treated for prostate cancer | | |
| Yes | 13 | 3.1 |
| No | 407 | 96.9 |
| Knowing someone affected by prostate cancer | | |
| Yes | 213 | 50.8 |
| No | 206 | 49.2 |
| Anxious/depressed feelings | | |
| Yes | 48 | 11.2 |
| No | 377 | 88.3 |
| Missing | 2 | 0.5 |
| Willingness to pay for prostate cancer screening | | |
| Yes | 339 | 79.4 |
| No | 76 | 17.8 |
| Missing | 12 | 2.8 |
Men's preferences for prostate cancer screening based on a panel latent class logit model with three latent classes
| Constant | 3.16*** | 9.71 | 4.67*** | 13.50 | −0.65* | −1.90 |
| Risk reduction of PC death (per 10%) | 0.93*** | 8.63 | 0.40*** | 2.90 | 0.82*** | 5.24 |
| Screening interval | ||||||
| Every year | 0.10** | 1.99 | −0.05 | −0.77 | −0.20** | −2.43 |
| Every 2 years | 0.20*** | 3.97 | 0.09 | 1.47 | 0.21*** | 2.89 |
| Every 3 years | −0.02 | −0.31 | −0.02 | −0.24 | −0.07 | −0.84 |
| Risk unnecessary biopsy (per 10%) | −0.10** | −2.57 | −0.27*** | −6.09 | −0.03 | −0.70 |
| Risk unnecessary treatment (per 10%) | −0.10*** | −5.30 | −0.04* | −1.77 | −0.17*** | −8.67 |
| Out-of-pocket costs (per €100) | 0.07 | 0.40 | −1.32*** | −5.40 | −1.10*** | −4.65 |
| Risk reduction PC death × costs | 0.06*** | 2.72 | −0.01 | −0.09 | 0.02 | 0.59 |
| Biopsy × costs | 0.07*** | 3.37 | 0.04 | 1.61 | 0.03 | 1.12 |
| Treatment × costs | −0.01 | −0.35 | 0.05** | 2.33 | 0.05*** | 3.09 |
| Risk reduction PC death × biopsy | −0.02** | −1.99 | 0.07*** | 5.59 | −0.03** | −2.29 |
| Costs2 | −0.07*** | −5.16 | 0.01 | 0.28 | 0.10** | 2.19 |
| Risk reduction PC death2 | −0.18*** | −5.98 | 0.03 | 1.55 | −0.06*** | −3.33 |
| Constant | 1.62*** | 7.03 | 0.69*** | 2.68 | — | — |
| Higher eduction | −0.74** | −2.35 | −0.70* | −1.86 | — | — |
| Depression | −1.73*** | −3.88 | −0.45 | −1.00 | — | — |
| Willingness to pay (per €100) | 0.25** | 2.97 | 0.02 | 0.29 | — | — |
| Average | 0.608 | | 0.230 | | 0.162 | |
| Log-likelihood | −4334.89 | |||||
| AIC | 1.32 | |||||
| BIC | 1.37 | |||||
| Pseudo | 0.41 | |||||
Abbreviations: Coeff.=coefficient; PC=prostate cancer.
***, **, * denotes significance at 1%, 5%, and 10%, respectively.
Effects coded variable used for frequency of a blood test (reference level=screening every 4 years; the value of this level equals the negative sum of the coefficients of the included attribute levels).
Number of observations=6.669.
Willingness to pay to achieve an improvement in one of the prostate screening attributes
| Mortality reduction | 187.6 (140.6 to 257.8) | With 10% more prostate cancer-related mortality reduction |
| Screening interval | 9.7 (−24.9 to 46.5) | Every year instead of every 4 years |
| | 86.9 (48.2 to 136.8) | Every 2 years instead of every 4 years |
| | −12.0 (−50.2 to 27.4) | Every 3 years instead of every 4 years |
| Unnecessary treatment | 37.6 (26.7 to 53.0) | With 10% less risk of unnecessary treatments |
| Unnecessary biopsy | 33.4 (22.5 to 48.4) | With 10% less risk of unnecessary biopsies |
Abbreviations: CI=confidence interval; €=euro; WTP=willingness to pay.
CI=95% confidence interval based on the Krinsky Robb method adjusted for class probabilities.
The average values of the interactions are taken into account (i.e., costs=€112.50; mortality reduction=27.5% unnecessary treatment=37.5% unnecessary biopsy=50%).
Willingness to trade mortality risk to achieve an improvement in one of the prostate screening attributes
| Unnecessary treatment | 2.0 (1.6 to 2.4) | With 10% less risk of unnecessary treatments |
| Screening interval | 0.5 (−1.3 to 2.4) | Every year instead of every 4 years |
| | 4.6 (2.8 to 6.4) | Every 2 years instead of every 4 years |
| | −0.7 (−2.8 to 1.4) | Every 3 years instead of every 4 years |
| Unnecessary biopsy | 1.8 (1.3 to 2.3) | With 10% less risk of unnecessary biopsies |
| Out-of-pocket costs | 5.5 (3.9 to 7.1) | With €100 lower out-of-pocket costs |
Abbreviations: CI=confidence interval; WTP=willingness to pay.
CI=95% confidence interval based on the Krinsky Robb method adjusted for class probabilities
The average values of the interactions are taken into account (i.e., costs=€112.50; mortality reduction=27.5% unnecessary treatment=37.5% unnecessary biopsy=50%).